May 17, 2017 / 4:38 PM / 2 months ago

BRIEF-Pharma Mar to market anti-tumor compound lurbinectedin in Asia-Pacific region

1 Min Read

May 17 (Reuters) - Pharma Mar SA:

* ENTERS LICENSING AGREEMENT WITH SINGAPORE COMPANY TO MARKET ITS ANTI-TUMOR COMPOUND LURBINECTEDIN IN ASIA-PACIFIC REGION

* TO RECEIVE AN UPFRONT PAYMENT FOLLOWED BY REMUNERATIONS UPON ACHIEVING REGULATORY AND SALES MILESTONES

* AGREEMENT INCLUDES STA SUBSCRIPTION OF NEW SHARES OF PHARMAMAR EQUIVALENT TO 0.2 PERCENT CAPITAL AT 4.75 EURO PER SHARE Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below